

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

mTOR Polyclonal Antibody

RRID:AB_2764355

Type: Antibody

Proper Citation

ABclonal Cat# A2445, RRID:AB_2764355

Antibody Information

URL: http://antibodyregistry.org/AB_2764355

Proper Citation: ABclonal Cat# A2445, RRID:AB_2764355

Target Antigen: mTOR

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications:WB, IHC, IF, IP

Antibody Name: mTOR Polyclonal Antibody

Description: This polyclonal targets mTOR

Target Organism: rat, mouse, human

Antibody ID: AB_2764355

Vendor: ABclonal

Catalog Number: A2445

Record Creation Time: 20231110T033217+0000

Record Last Update: 20260831T224409+0000

Ratings and Alerts

No rating or validation information has been found for mTOR Polyclonal Antibody.

No alerts have been found for mTOR Polyclonal Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu C, et al. (2026) Fangchinoline alleviates hypertensive heart failure via PGC-1 β /STAT6/PPAR γ activation of mitophagy against ferroptosis. British journal of pharmacology.

Shen Z, et al. (2026) Plasmin promotes hepatocellular carcinoma invasion and metastasis via CXCR4-mediated activation of PI3K/AKT/mTOR signaling. Oncogene, 45(19), 1815.

Chen J, et al. (2025) OTUD4 inhibits ferroptosis by stabilizing GPX4 and suppressing autophagic degradation to promote tumor progression. Cell reports, 44(5), 115681.

Yang X, et al. (2024) Regulation of glycolysis-derived L-lactate production in astrocytes rescues the memory deficits and A β burden in early Alzheimer's disease models. Pharmacological research, 208, 107357.

Wang Y, et al. (2023) Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling. Drug development research.